

BUSINESS NEWS – 9th MARCH 2022

[Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates](#)

“Committed to chasing the miracles of science, we look forward to working with Adagene to design antibodies that can help us deliver on our mission to bring transformative new medicines to people living with cancer,” said Valeria Fantin, Global Head of Oncology Research, Sanofi. “Adagene’s antibody platform should help us to precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines.”

[Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degradar Therapies](#)

"At Blueprint Medicines, we strive to stay on the cutting edge by identifying emerging precision medicine technologies with potential to complement and further amplify our highly productive research platform," said Fouad Namouni, M.D., President of Research and Development at Blueprint Medicines. "Recent scientific advancements in the field of targeted protein degradation have revealed opportunities to expand our core kinase capabilities and explore new ways to treat difficult to drug and novel targets, as well as address on-target resistance mechanisms. This collaboration with Proteovant Therapeutics will enable us to expand our platform more quickly in our mission to improve outcomes for patients with cancer and blood disorders."

[Genome & Co. and MSD to evaluate ‘GEN-001’ + KEYTRUDA® combination in Ph 2 clinical trial in biliary tract cancer patients](#)

Dr. Jisoo Pae, CEO of Genome and Company, said, “Genome and Company has established clinical trial collaborations to evaluate ‘GEN-001’ with both anti-PD-L1 and anti-PD-1 therapies through agreements with MSD, Merck KGaA, Darmstadt, Germany and Pfizer, which shows that the company is being recognized for its innovative technology by global immuno-oncology companies.” He added, “Through this clinical trial collaboration, we look forward to evaluating the potential additive benefit of ‘GEN-001’ in combination with KEYTRUDA® as treatment for patients with biliary tract cancer.”

[Helsinn Group and BridgeBio Pharma to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.](#)

Giorgio Calderari, Helsinn Group CEO commented, “We are delighted to gain the exclusive license to commercialize infigratinib in the U.S. This perfectly complements our recently announced Fully Integrated Targeted Therapy (FITT) Strategy and will utilize our unique capabilities and expertise to take products through development and to patients living with cancer across the globe. BridgeBio is a great partner, and we are looking forward to continuing our relationship with them through our non-exclusive collaboration framework to propose co-development and co-commercialization opportunities for preclinical precision oncology programs.”